Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 15 Jul 2015

Ferring bets on bacteriophages to treat inflammatory bowel disease

Bacteriophages have been instinctively killing bacteria for millions of years. These natural bacteria predators represent a potential alternative to antibiotics and Ferring Pharmaceuticals wants to use them against inflammatory bowel disease. The Swiss pharma joined forces with phages specialist Intralytix to manufacture these viruses for clinical purposes. Bacteriophages can be very selective when it comes […]

July 15, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Jul 2015

Newron’s ressurection story continues with a FDA Orphan Drug designation

New success for Newron Pharmaceuticals. The FDA approved Orphan Drug designation to its new chemical entity Sarizotan, designed to treat patients suffering from Rett syndrome. This decision fits the one from the European Medicine Agency, whose Committee for Orphan Medical Products positively reviewed the drug last month. The Italian pharma company Newron with a market […]

July 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Jul 2015

ReNeuron backed by First-Class Investor Woodford to advance Stem Cell Therapy

The stem cell therapy developer ReNeuron raised €96M to conduct further clinical trials of its pipeline, and more specifically to pursue potential stroke, eye disease, and cancer treatments. The financial placement is supported by the already major shareholder Woodford Investment Management, allowing the latter to possess more than one-third of the company shares. ReNeuron, a […]

July 13, 2015 - 2 minutesmins - By Philip Hemme

bactman synthetic biology videogame paris supbiotech

News and Trends 12 Jul 2015

Cool iGEM Project: Creating the first Synthetic Biology-based Video Game

It’s iGEM- Time, the world’s biggest synthetic biology competition! Since 2004, students are competing to create, explore and share their innovative ideas in the hot field of synthetic biology. All the teams then go to Boston (not at the MIT anymore since it’s stopped organizing the competition) to be judged and win a prize. Each year, […]

July 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Jul 2015

Sanofi to solve Growing Resistance against Malarial Treatments

Sanofi extended its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new combination therapy against malaria, the deadliest parasitic disease worldwide. The difficult access and the fear of a growing resistance to the existing treatments highlight the importance of this partnership. Atemisinin-based combination therapies (ACT) are at this moment the most efficient […]

July 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 10 Jul 2015

Greenovation: Using Moss as a Drug Production Factory

Factor H, a key component of the immune system that is missing in patients suffering from atypical hemolytic uremic syndrome (aHUS) was effectively produced in the moss Physcomitrella patens. In collaboration with the University of Freiburg, Greenovation now aims to humanize the protein to suit it for clinical use. The complement system is part of […]

July 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 9 Jul 2015

Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

Antibiotic resistance is a public health problem worldwide. According to WHO, by 2050, over 10 million people will die every year. Microbiomics is a fast evolving field which could play an important role in fighting these resistant bacteria. And CRISPR is literally seen as the biggest Biotech discovery of this century. So, here’s a crazy thought… what would […]

July 9, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 8 Jul 2015

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

Good news for patients suffering from cystic fibrosis! Imperial Innovations‘ patented gene therapy could improve the patients’ breathing provoking any side effects. An innovation that could help fulfill this unmet medical need. Cystic fibrosis is the most common deadly genetic disease in Europe. Gene deficiency leads to thickening mucus that obstructs lungs and results in […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Jul 2015

CureVac’s mRNA Therapy is Working Against Prostate Cancer

mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

Novo Nordisk cancels its collaboration deal with Zosano Pharma. The diabetes drug semaglutine won’t be delivered with the microneedle patch technology, developed from the latter. Zosano’s patch technology uses thin titanium microprojections to deliver drugs that cannot permeate the outer layer of the skin. According to Zosano, the system was tested on 400 patients in […]

July 7, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system. To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate […]

July 6, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

Two weeks ago, I travelled through Denmark to interview 15 CEOs to film its biotech industry, Labiotech Tour Denmark. Amongst them was Martin Bonde, CEO of Dansk Biotech and former CEO of Epitherapeutics which was sold at €60M to Gilead (the 2nd largest Biotech in the world). I just read he is switching to Vaccibody the Norwegian Biotech and […]

July 6, 2015 - 1 minutemin - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Philip Hemme

About

Articles by Philip Hemme

Ferring bets on bacteriophages to treat inflammatory bowel disease

Newron’s ressurection story continues with a FDA Orphan Drug designation

ReNeuron backed by First-Class Investor Woodford to advance Stem Cell Therapy

Cool iGEM Project: Creating the first Synthetic Biology-based Video Game

Sanofi to solve Growing Resistance against Malarial Treatments

Greenovation: Using Moss as a Drug Production Factory

Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

CureVac’s mRNA Therapy is Working Against Prostate Cancer

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Philip Hemme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!